| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.6 | 2.4 |
| Profit before tax | -16.5 | -36.9 |
| Net income | -16.5 | -36.5 |
| EPS (diluted, $ a share) | $-0.32 | $-0.68 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -74.3% |
|---|
10-Q filed with the SEC, NASDAQ: PRTA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Prothena Corp Public Ltd Co: key numbers
- Share price
- $8.26Close, Nov 17
- Market cap
- $424M
- Shares outstanding
- 51.35MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Prothena Corp Public Ltd Co
All →Prothena Corp Public Ltd Insider William P. Scully Buys $1.19M of Stock
William P. Scully bought 140,000 shares of Prothena Corp Public Ltd Co at $8.53 a share, worth $1.19M in total on Nov 9, 2026. Shares held after the trade: 977,000 (+16.7%).
- Value
- $1.19M
- Shares
- 140,000
- Price
- $8.53
- Holding change
- +16.7%
- Trade date
- Nov 9, 2026
Prothena Corp Public Ltd Financial Results
Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher Barrett’s Esophagus test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.
- Term
- Q3 2026
“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”
Derek Maetzold, president and chief executive officer of Castle Biosciences
“Overall, our third-quarter results reflect the strength of our portfolio, consistent execution and continued progress toward our long-term growth objectives. I want to thank the entire Castle team for their dedication, hard work and unwavering commitment to improving patient care.”
Derek Maetzold, president and chief executive officer of Castle Biosciences
Prothena Corp Public Ltd Deal Termination with Bristol Myers Squibb
Bristol Myers Squibb (BMS) has terminated its exclusive global license agreement for PRX019 with Prothena following an internal strategic review. As a result of the termination, effective January 28, 2027, Prothena is no longer eligible to receive up to $617.5 million in potential development, regulatory, and sales milestones. BMS will continue to develop moponetug (PRX005) under a separate ongoing collaboration agreement.
- Counterparty
- Bristol Myers Squibb
Prothena Corp Public Ltd Insider William P. Scully Buys $1.22M of Stock
William P. Scully bought 150,000 shares of Prothena Corp Public Ltd Co at $8.07 to $8.19 a share (average $8.15) in 2 transactions, worth $1.22M in total between Oct 22, 2026 and Oct 23, 2026. Shares held after the trade: 1,187,000 (+4.4%).
- Value
- $1.22M
- Shares
- 150,000
- Average price
- $8.15
- Holding change
- +4.4%
- Trade date
- Oct 22, 2026 to Oct 23, 2026
Prothena Corp Public Ltd Insider William P. Scully Buys $920K of Stock
William P. Scully bought 110,000 shares of Prothena Corp Public Ltd Co at $8.35 to $8.46 a share (average $8.36) in 2 transactions, worth $920K in total between Oct 13, 2026 and Oct 14, 2026. Shares held after the trade: 1,037,000 (+1.0%).
- Value
- $920K
- Shares
- 110,000
- Average price
- $8.36
- Holding change
- +1.0%
- Trade date
- Oct 13, 2026 to Oct 14, 2026
Prothena Corp Public Ltd Insider William P. Scully Buys $1.82M of Stock
William P. Scully bought 215,000 shares of Prothena Corp Public Ltd Co at $8.40 to $8.57 a share (average $8.47) in 2 transactions, worth $1.82M in total between Oct 7, 2026 and Oct 8, 2026. Shares held after the trade: 529,000 (+20.5%).
- Value
- $1.82M
- Shares
- 215,000
- Average price
- $8.47
- Holding change
- +20.5%
- Trade date
- Oct 7, 2026 to Oct 8, 2026